ArticleAdvanced healthcare materials2025
Induction of Nephron-Ductal Dual Lineages via Early Retinoic Acid Signaling Establishes a Platform for Fully Patterned Kidney Organoids.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026Review
- Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer.Signal transduction and targeted therapy · 2026Article
- Induction of Nephron-Ductal Dual Lineages via Early Retinoic Acid Signaling Establishes a Platform for Fully Patterned Kidney Organoids.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Kidney organoids are powerful tools for renal disease modeling and nephrotoxicity screening, yet their limited structural complexity-particularly the underdevelopment of ureteric bud (UB) lineages-remains a major limitation. A novel differentiation protocol is developed that short-term activation of retinoic acid (RA) signaling during the early intermediate mesoderm (IM) stage, enabling co-induction of anterior and posterior IM lineages. This eliminates the need for UB co-culture and supports the formation of kidney organoids containing complete nephron segments. BMP7 treatment during the maturation phase mimics UB-derived signals, further enhancing tubular maturation. Single-cell transcriptomic analysis confirms that RA activation promotes dual IM induction at early stages, while BMP7 enhances organoid maturity. These dual IMs enable the generation of tubule and collecting duct organoids, which serve as segment-specific models for renal reabsorption, efflux, and nephron-targeted drug response assessment. Furthermore, the organoids are integrated into a networking cell culture system with enterocytes and hepatocytes, establishing a physiologically integrated model for systemic drug evaluation. This platform enables more accurate in vitro analysis of drug absorption, metabolism, and nephrotoxicity, including NSAID-induced injury. Overall, this approach offers a robust, scalable, and physiologically relevant platform for next-generation renal modeling and pharmacological research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.